Profund Advisors LLC Buys 14,367 Shares of Novo Nordisk A/S $NVO

Profund Advisors LLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 162.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,210 shares of the company’s stock after buying an additional 14,367 shares during the period. Profund Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,181,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in NVO. Franklin Resources Inc. boosted its holdings in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares during the period. Capital International Investors lifted its holdings in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the period. Boston Partners bought a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $310,199,000. Clear Street Group Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter valued at $56,378,000. Finally, Armistice Capital LLC bought a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $40,841,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NVO has been the topic of a number of research reports. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Finally, Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Up 1.8%

Shares of NVO stock opened at $45.07 on Thursday. The stock’s fifty day moving average price is $40.05 and its 200 day moving average price is $46.51. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a market cap of $201.23 billion, a price-to-earnings ratio of 10.58, a price-to-earnings-growth ratio of 3.94 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The business had revenue of $10.85 billion during the quarter. On average, research analysts expect that Novo Nordisk A/S will post 3.47 earnings per share for the current fiscal year.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deutsche Bank said Novo Nordisk remains cautiously optimistic on its key cagrisema obesity study, suggesting the upcoming RD11 readout could outperform the disappointing prior trial and potentially improve investor sentiment. Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
• Positive Sentiment: Recent Wegovy data showed strong weight-loss efficacy, better physical function, and favorable body-composition results, while oral Wegovy also compared well with Eli Lilly’s oral GLP-1 candidate on weight loss, tolerability, and patient preference. How New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment Story
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Novo Nordisk, signaling slightly better earnings expectations and some underlying confidence in the business outlook.
• Positive Sentiment: Denmark’s 1.9% GDP growth was boosted by pharmaceutical strength linked to Novo Nordisk, underscoring the company’s continued importance and strength in its core market. Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth
• Neutral Sentiment: Novo Nordisk continues to advance additional obesity-maintenance and cagrilintide studies, which keeps its pipeline active but does not yet change the near-term earnings picture. Novo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance Drugs
• Neutral Sentiment: Novo Nordisk is also expanding beyond obesity through a Parkinson’s program transfer and other strategic moves, but these are longer-term developments with limited immediate stock impact. Novo Nordisk Expands Parkinson’s Bet With AI Partner And Upside Potential
• Negative Sentiment: Eli Lilly’s encouraging oral GLP-1 results highlight intensifying competition in the obesity-pill market, which could pressure Novo Nordisk’s future market share and pricing power. From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook (NVO)
• Negative Sentiment: Other competitors, including Viking Therapeutics, are also developing oral weight-loss pills, adding to the competitive overhang on Novo Nordisk’s GLP-1 franchise. Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics’ Pill Could Crash the Weight-Loss Party

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.